儿童方案BFM90治疗费城染色体阴性成年人急性淋巴细胞白血病  

Retrospective analysis of the effectiveness of a pediatric protocol BFM90 in adults with Philadelphia chromosome-negative acute lymphoblastic leukemia

作　　者：彭利晖[1] 胡灯明[1] 王三斌[1] 

机构地区：[1]成都军区昆明总医院血液科,昆明650032

出　　处：《白血病．淋巴瘤》2010年第6期331-333,337,共4页Journal of Leukemia & Lymphoma

摘　　要：目的 分析费城染色体阴性（Ph-）成年急性淋巴细胞性白血病（ALL）患者应用儿童ALL的BFM90化疗方案治疗后的远期疗效.方法 2004年8月至2007年10月,共60例Ph-成年ALL患者[中位年龄40（18-60）岁],接受BFM90方案治疗,并进行回顾性分析,其治疗结果同35例接受Hyper-CVAD方案化疗的患者[中位年龄42（18-56）岁]进行历史对照.结果 BFM90化疗42个月的完全缓解（CR）率、总生存（OS）率、无事件生存（EFS）率分别为93%（56例）、65%（39例）和60%（36例）.45岁是本组年龄因素中影响预后的主要截断值.BFM90组CR、OS和EFS优于Hyper-CVAD方案历史对照组（均为P＜0.05）.结论 与成年人Hyper-CVAD方案相比,儿童ALL的BFM90化疗方案治疗成年人ALL有更好的疗效.Objective To retrospectively analyze the efficacy of a pediatric treatment protocol,BFM90,in adult patients with acute lymphobiastic leukemia （ALL） up to the age of 60 years. Methods From August 2004 to October 2007,60 adult patients （median age,40 years; range,18 to 60 years） with Philadelphia chromosome-negative ALL were treated with the BFM90 protocol. Clinical effect were historically compared with that of the 35 patients （median age,42 years; range,18 to 56 years） who were treated with Hyper-CVAD protocol. Results At 42 months,complete remission （CR） rate,event-free survival （EFS） and overall survival （OS） rates were 93 % （56 patients）,60 % （36 patients） and 65 % （39 patients）,respectively.Age is an important prognostic factor,with 45 years of age as best cutoff. CR （P=0.02）,OS （P 〈0.001）,and EFS （P 〈0.001） of BFM90 were compared superiorly with that of the previous Hyper-CVAD experience.Conclusion These results suggest that pediatric protocol superior to the outcome of adult patients with Philadelphia chromosome-negative ALL.

关 键 词：费城染色体阴性 白血病 淋巴细胞 急性 成年人 抗肿瘤联合化疗方案 

分 类 号：R733.71[医药卫生—肿瘤]